☰

Patrick J. Roberts, Ph.D. - Publications

Affiliations: 
2007 Pharmaceutical Sciences University of North Carolina, Chapel Hill, Chapel Hill, NC 
Area:
Pharmacology, Oncology, Pathology
Tree Info Grants Similar researchers PubMed Report error

46 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Dietrich C, Trub A, Ahn A, Taylor M, Ambani K, Chan KT, Lu KH, Mahendra CA, Blyth C, Coulson R, Ramm S, Watt AC, Matsa SK, Bisi J, Strum J, ... Roberts P, et al. INX-315, a selective CDK2 inhibitor, induces cell cycle arrest and senescence in solid tumors. Cancer Discovery. PMID 38047585 DOI: 10.1158/2159-8290.CD-23-0954  0.304
2020 Roberts PJ, Kumarasamy V, Witkiewicz AK, Knudsen ES. Chemotherapy and CDK4/6 inhibitors: Unexpected bedfellows. Molecular Cancer Therapeutics. PMID 32546660 DOI: 10.1158/1535-7163.Mct-18-1161  0.408
2019 Weiss JM, Csoszi T, Maglakelidze M, Hoyer RJ, Beck JT, Gomez MD, Lowczak A, Aljumaily R, Lima CMR, Boccia RV, Hanna W, Nikolinakos P, Chiu VK, Owonikoko TK, Schuster SR, ... ... Roberts PJ, et al. Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small cell lung cancer receiving 1st-line chemotherapy: a Phase 1b/randomized Phase 2 trial. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 31504118 DOI: 10.1093/Annonc/Mdz278  0.385
2019 O'Shaughnessy J, Wright G, Thummala A, Danso M, Popovic L, Pluard T, Cheung E, Han H, Daniel B, Vojnovic Z, Vasev N, Ling M, Richards D, Wilks S, Milenkovic D, ... ... Roberts P, et al. Abstract PD1-01: Trilaciclib (T), a CDK4/6 inhibitor, dosed with gemcitabine (G), carboplatin (C) in metastatic triple negative breast cancer (mTNBC) patients: Preliminary phase 2 results Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-Pd1-01  0.36
2019 Goodwin CM, Javaid S, Waters AM, Papke B, Yang R, Pierobon M, Freed DM, Roberts PJ, Cox AD, Wood KC, Petricoin EF, McRee AJ, Der CJ. Abstract LB-287: Combination therapies with CDK4/6 inhibitors to treat KRAS-mutant pancreatic cancer Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Lb-287  0.578
2019 Dai B, Freed DM, Sorrentino JA, Augustine JJ, Hughes TG, Kang Y, Roberts PJ, Fleming JB, Kim MP. Abstract 4732: CDK4/6 inhibition with lerociclib (G1T38) enhances response to PI3K or ERK inhibitors in high-throughput, ex vivo pancreatic PDX screens Cancer Research. 79: 4732-4732. DOI: 10.1158/1538-7445.Am2019-4732  0.404
2019 Freed DM, Hall CR, Strum JC, Roberts PJ. Abstract 4415: CDK4/6 inhibition with lerociclib (G1T38) delays acquired resistance to targeted therapies in preclinical models of non-small cell lung cancer Cancer Research. 79: 4415-4415. DOI: 10.1158/1538-7445.Am2019-4415  0.415
2018 Sorrentino JA, Lai A, Weiss JM, Dragnev KH, Owonikoko TK, Adler S, Antal JM, Malik RK, Roberts PJ. Trilaciclib (trila) preserves and enhances immune system function in extensive-stage small cell lung cancer (ES-SCLC) patients receiving first-line chemotherapy. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: viii598. PMID 32137593 DOI: 10.1093/Annonc/Mdy298.007  0.347
2018 Dragnev KH, Owonikoko TK, Csoszi T, Maglakelidze M, Beck JT, Domine Gomez M, Lowczak A, Fulop A, Hoyer RJ, Hanna W, Lowry P, Aljumaily R, Chiu VK, Bulat I, Yang Z, ... Roberts PJ, et al. Trilaciclib (T) decreases multi-lineage myelosuppression in extensive-stage small cell lung cancer (ES-SCLC) patients receiving first-line chemotherapy. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: viii597. PMID 32137589 DOI: 10.1093/Annonc/Mdy298.002  0.332
2018 Lai AY, Sorrentino JA, Strum JC, Roberts PJ. Abstract 1752: Transient exposure of trilaciclib, a CDK4/6 inhibitor, modulates gene expression in tumor immune infiltrates to promote a pro-inflammatory tumor microenvironment Cancer Research. 78: 1752-1752. DOI: 10.1158/1538-7445.Am2018-1752  0.371
2018 Sorrentino JA, Freed DM, Bisi JE, Strum JC, Roberts PJ. Abstract 1522: The CDK4/6 inhibitor G1T38 enhances response to targeted therapies in preclinical models of non-small cell lung cancer Cancer Research. 78: 1522-1522. DOI: 10.1158/1538-7445.Am2018-1522  0.438
2018 Roberts P, Lai A, Sorrentino J, Malik R. Trilaciclib (G1T28), a CDK4/6 inhibitor, enhances the efficacy of combination chemotherapy and immune checkpoint inhibitor treatment in preclinical models Annals of Oncology. 29: iii4. DOI: 10.1093/Annonc/Mdy046.013  0.349
2017 Deng J, Wang ES, Jenkins RW, Li S, Dries R, Yates K, Chhabra S, Huang W, Liu H, Aref AR, Ivanova E, Paweletz CP, Bowden M, Zhou CW, Herter-Sprie GS, ... ... Roberts PJ, et al. CDK4/6 Inhibition Augments Anti-Tumor Immunity by Enhancing T Cell Activation. Cancer Discovery. PMID 29101163 DOI: 10.1158/2159-8290.Cd-17-0915  0.357
2017 He S, Roberts PJ, Sorrentino JA, Bisi JE, Storrie-White H, Tiessen RG, Makhuli KM, Wargin WA, Tadema H, van Hoogdalem EJ, Strum JC, Malik R, Sharpless NE. Transient CDK4/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustion. Science Translational Medicine. 9. PMID 28446688 DOI: 10.1126/Scitranslmed.Aal3986  0.386
2017 Bisi JE, Sorrentino JA, Jordan JL, Darr DD, Roberts PJ, Tavares FX, Strum JC. Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors. Oncotarget. PMID 28418845 DOI: 10.18632/Oncotarget.16216  0.399
2017 Rocha Lima CMS, Roberts PJ, Priego VM, Divers SG, Thomas MB, Boccia RV, Stabler K, Andrews E, Malik RK, Aljumaily R, Hamm JT, Chiu VK, Richards DA, Nikolinakos P, Hussein MA, et al. Trilaciclib (G1T28): A cyclin dependent kinase 4/6 inhibitor, in combination with etoposide and carboplatin (EP) for extensive stage small cell lung cancer (ES-SCLC)—Phase 1b results. Journal of Clinical Oncology. 35: 8568-8568. DOI: 10.1200/Jco.2017.35.15_Suppl.8568  0.321
2017 Sorrentino JA, Lai AY, Strum JC, Roberts PJ. Abstract 5628: Trilaciclib (G1T28), a CDK4/6 inhibitor, enhances the efficacy of combination chemotherapy and immune checkpoint inhibitor treatment in preclinical models Immunology. 77: 5628-5628. DOI: 10.1158/1538-7445.Am2017-5628  0.35
2017 Hart L, Roberts P, Ferrarotto R, Bordoni R, Conkling P, Patil T, Rocha Lima CM, Owonikoko T, Schuster S, Jotte R, Hoyer R, Stabler K, Makhuli K, Aljumaily R, Edenfield W, et al. P1.07-002 G1T28, a Cyclin Dependent Kinase 4/6 Inhibitor, in Combination with Topotecan for Previously Treated Small Cell Lung Cancer: Preliminary Results Journal of Thoracic Oncology. 12: S696. DOI: 10.1016/J.Jtho.2016.11.913  0.406
2017 Guijarro I, Poteete A, Ferrarotto R, Denning W, Hamdi H, Roberts P, Malik R, Bisi J, Sorrentino J, Strum J, Roarty E, Heymach J. P2.03a-048 The CDK4/6 Inhibitor G1T28 Protects Immune Cells from Cisplatin-Induced Toxicity in vivo and Inhibits SCLC Tumor Growth Journal of Thoracic Oncology. 12: S918. DOI: 10.1016/J.Jtho.2016.11.1258  0.327
2016 Bisi JE, Sorrentino JA, Roberts PJ, Tavares FX, Strum JC. Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-induced Myelosuppression. Molecular Cancer Therapeutics. PMID 26826116 DOI: 10.1158/1535-7163.Mct-15-0775  0.378
2016 Guijarro I, Denning W, Ferrarotto R, Poteete A, Giri U, Bisi JE, Sorrentino JA, Roberts PJ, Strum JC, Malik RK, Roarty E, Heymach J. The CDK4/6 inhibitor G1T28 to protect immune cells and fibroblasts from chemotherapy and radiation-induced toxicity in vitro and to maintain efficacy of chemotherapy in SCLC Rb-deficient cells. Journal of Clinical Oncology. 34: e20099-e20099. DOI: 10.1200/Jco.2016.34.15_Suppl.E20099  0.38
2016 Lima CMSR, Roberts PJ, Priego VM, Divers SG, Thomas M, Boccia R, Webb RT, Stabler K, Makhuli KM, Malik R, Aljumaily R. Abstract CT151: G1T28, a cyclin dependent kinase 4/6 inhibitor, in combination with etoposide and carboplatin for extensive stage small cell lung cancer (ES-SCLC): preliminary results Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Ct151  0.411
2016 Sorrentino JA, Bisi JE, Roberts PJ, Strum JC. Abstract 2824: G1T38, a novel, oral, potent and selective CDK4/6 inhibitor for the treatment of Rb competent tumors Cancer Research. 76: 2824-2824. DOI: 10.1158/1538-7445.Am2016-2824  0.414
2016 Roberts P, He S, Schvartsman G, Patil T, Sorrentio J, Bisi J, Hoyer R, Schuster S, Strum J, Heymach J, Ferrarotto R, Sharpless N, Shapiro G, Malik R. G1T28, a CDK4/6 inhibitor, preserves T lymphocyte function from damage by cytotoxic chemotherapy European Journal of Cancer. 69: S143-S144. DOI: 10.1016/S0959-8049(16)33026-X  0.316
2015 Roberts PJ, White HS, Sorrentino JA, Tadema H, Sale M, Tiessen RG, Bisi JE, Makhuli KM, Hoogdalem Ev, Malik RK, Strum JC. Evaluation of targeted bone marrow arrest by G1T28, a CDK4/6 inhibitor in clinical development to reduce chemotherapy-induced myelosuppression. Journal of Clinical Oncology. 33: 2529-2529. DOI: 10.1200/Jco.2015.33.15_Suppl.2529  0.336
2015 Tiessen RG, Roberts PJ, Sorrentino JA, White HS, Makhuli KM, Bisi JE, Strum JC, Hoogdalem Ev, Malik RK. First-in-human Phase 1 safety, PK, and PD study of the CDK4/6 inhibitor G1T28. Journal of Clinical Oncology. 33: 2527-2527. DOI: 10.1200/Jco.2015.33.15_Suppl.2527  0.37
2015 Sorrentino JA, He S, Bisi JE, Roberts PJ, Strum JC, Sharpless NE. Abstract 941: G1T28-1, a novel CDK4/6 inhibitor, protects murine hematopoietic stem and progenitor cells from cytotoxic chemotherapy Cancer Research. 75: 941-941. DOI: 10.1158/1538-7445.Am2015-941  0.319
2015 Bisi JE, White HS, Sorrentino JA, Roberts PJ, Strum JC. Abstract 1784: Pre-clinical characterization of G1T28-1, a novel CDK 4/6 inhibitor for protection of bone marrow from cytotoxic chemotherapies Cancer Research. 75: 1784-1784. DOI: 10.1158/1538-7445.Am2015-1784  0.396
2014 Zhao N, Wilkerson MD, Shah U, Yin X, Wang A, Hayward MC, Roberts P, Lee CB, Parsons AM, Thorne LB, Haithcock BE, Grilley-Olson JE, Stinchcombe TE, Funkhouser WK, Wong KK, et al. Alterations of LKB1 and KRAS and risk of brain metastasis: comprehensive characterization by mutation analysis, copy number, and gene expression in non-small-cell lung carcinoma. Lung Cancer (Amsterdam, Netherlands). 86: 255-61. PMID 25224251 DOI: 10.1016/J.Lungcan.2014.08.013  0.32
2014 DiRocco DP, Bisi J, Roberts P, Strum J, Wong KK, Sharpless N, Humphreys BD. CDK4/6 inhibition induces epithelial cell cycle arrest and ameliorates acute kidney injury. American Journal of Physiology. Renal Physiology. 306: F379-88. PMID 24338822 DOI: 10.1152/Ajprenal.00475.2013  0.3
2014 Roberts PJ, Darr DB, Bisi JE, Strum JC. Abstract 1322: Novel CDK4/6 inhibitors provide robust antitumor activity in a murine model of luminal breast cancer Cancer Research. 74: 1322-1322. DOI: 10.1158/1538-7445.Am2014-1322  0.395
2013 Usary J, Zhao W, Darr D, Roberts PJ, Liu M, Balletta L, Karginova O, Jordan J, Combest A, Bridges A, Prat A, Cheang MC, Herschkowitz JI, Rosen JM, Zamboni W, et al. Predicting drug responsiveness in human cancers using genetically engineered mice. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 4889-99. PMID 23780888 DOI: 10.1158/1078-0432.Ccr-13-0522  0.349
2013 Wilkerson MD, Schallheim JM, Hayes DN, Roberts PJ, Bastien RR, Mullins M, Yin X, Miller CR, Thorne LB, Geiersbach KB, Muldrew KL, Funkhouser WK, Fan C, Hayward MC, Bayer S, et al. Prediction of lung cancer histological types by RT-qPCR gene expression in FFPE specimens. The Journal of Molecular Diagnostics : Jmd. 15: 485-97. PMID 23701907 DOI: 10.1016/J.Jmoldx.2013.03.007  0.335
2013 Roberts PJ. Clinical use of crizotinib for the treatment of non-small cell lung cancer. Biologics : Targets & Therapy. 7: 91-101. PMID 23671386 DOI: 10.2147/Btt.S29026  0.376
2013 Roberts PJ, Stinchcombe TE. KRAS mutation: should we test for it, and does it matter? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 1112-21. PMID 23401440 DOI: 10.1200/Jco.2012.43.0454  0.373
2013 Um S, Chen J, Lee C, Sharpless NE, Roberts PJ, Hayes DN. Abstract 2400: Differential phosphorylation of signaling targets as a function of RAS mutation status and tumor histology in non-small cell lung cancer. Cancer Research. 73: 2400-2400. DOI: 10.1158/1538-7445.Am2013-2400  0.366
2012 Combest AJ, Roberts PJ, Dillon PM, Sandison K, Hanna SK, Ross C, Habibi S, Zamboni B, Müller M, Brunner M, Sharpless NE, Zamboni WC. Genetically engineered cancer models, but not xenografts, faithfully predict anticancer drug exposure in melanoma tumors. The Oncologist. 17: 1303-16. PMID 22993143 DOI: 10.1634/Theoncologist.2012-0274  0.322
2012 Roberts PJ, Usary JE, Darr DB, Dillon PM, Pfefferle AD, Whittle MC, Duncan JS, Johnson SM, Combest AJ, Jin J, Zamboni WC, Johnson GL, Perou CM, Sharpless NE. Combined PI3K/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer models. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 5290-303. PMID 22872574 DOI: 10.1158/1078-0432.Ccr-12-0563  0.399
2012 Chen Z, Cheng K, Walton Z, Wang Y, Ebi H, Shimamura T, Liu Y, Tupper T, Ouyang J, Li J, Gao P, Woo MS, Xu C, Yanagita M, Altabef A, ... ... Roberts PJ, et al. A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature. 483: 613-7. PMID 22425996 DOI: 10.1038/Nature10937  0.365
2012 Roberts PJ, Bisi JE, Strum JC, Combest AJ, Darr DB, Usary JE, Zamboni WC, Wong KK, Perou CM, Sharpless NE. Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy. Journal of the National Cancer Institute. 104: 476-87. PMID 22302033 DOI: 10.1093/Jnci/Djs002  0.401
2012 Mitin N, Roberts PJ, Chenette EJ, Der CJ. Posttranslational lipid modification of Rho family small GTPases. Methods in Molecular Biology (Clifton, N.J.). 827: 87-95. PMID 22144269 DOI: 10.1007/978-1-61779-442-1_6  0.644
2010 Roberts PJ, Stinchcombe TE, Der CJ, Socinski MA. Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 4769-77. PMID 20921461 DOI: 10.1200/Jco.2009.27.4365  0.517
2010 Wilkerson MD, Yin X, Hoadley KA, Liu Y, Hayward MC, Cabanski CR, Muldrew K, Miller CR, Randell SH, Socinski MA, Parsons AM, Funkhouser WK, Lee CB, Roberts PJ, Thorne L, et al. Lung squamous cell carcinoma mRNA expression subtypes are reproducible, clinically important, and correspond to normal cell types. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 4864-75. PMID 20643781 DOI: 10.1158/1078-0432.Ccr-10-0199  0.315
2008 Roberts PJ, Mitin N, Keller PJ, Chenette EJ, Madigan JP, Currin RO, Cox AD, Wilson O, Kirschmeier P, Der CJ. Rho Family GTPase modification and dependence on CAAX motif-signaled posttranslational modification. The Journal of Biological Chemistry. 283: 25150-63. PMID 18614539 DOI: 10.1074/Jbc.M800882200  0.648
2007 Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene. 26: 3291-310. PMID 17496923 DOI: 10.1038/Sj.Onc.1210422  0.493
2007 Hayes DN, Schallheim J, Roberts P, Lee C, Thorne L, Perou C, Parsons A, Socinski MA, Funkhouser W, Bernard P. Paraffin-based molecular diagnosis of lung cancer reproduces morphologic and molecular subtypes of lung cancer Journal of Clinical Oncology. 25: 7579-7579. DOI: 10.1200/Jco.2007.25.18_Suppl.7579  0.339
Show low-probability matches.